Psychopharmacology

Autism and Pervasive Developmental Disorders, Second Edition

Volumn , Issue , 2007, Pages 221-254

  Poustka, Fritz ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928597037     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544446.008     Document Type: Chapter

References (122)

1. Anderson, G. M., Freedman, D. X., Cohen, D. J. et al. (1987). Whole blood serotonin in autistic and normal subjects. Journal of Child Psychology and Psychiatry, 28, 885-900.
2. Anderson L. T., Campbell, M., Grega, D. M. et al. (1984). Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. American Journal of Psychiatry, 141, 1195-1202.
3. Anderson L. T., Campbell, M., Adams, P. et al. (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. Journal of Autism and Developmental Disorders, 19, 227-239.
4. Arnold, L. E., Vitiello, B., McDougle, C. et al. (2003). Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 1443-1450.
5. Belsito, K. M., Law, P A., Kirk, K. S., Landa, R. J., and Zimmerman, A.W (2001). Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 31, 175-181.
6. Bolman, W. M. and Richmond, J. A. (1999). A double-blind placebo controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. Journal of Autism and Developmental Disorders, 29, 191-194.
7. Branford, D., Bhaumik, S., and Naik, B. (1998). Selective serotonin re-uptake inhibitors for the treatment of pervasive and maladaptive behaviors of people with intellectual disability. Journal of Intellectual Disability Research, 42, 301-306.
8. Brodkin, E. S., Mc Dougle, C.J., Naylor, S. T., Cohen, D.J., and Price L. H. (1997). Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation. Journal of Child and Adolescent Psychopharmacology, 7, 109-21.
9. Buchsbaum, M. S., Hollander, E., Hazendar, M. M. et al. (2001). Effects of fluoxetine on regional cerebral metabolism in autistic spectrum disorder: a pilot study. International Journal ofNeu- ropsychopharmacology, 4, 119-125.
10. Buitelaar, J. K., van der Gaag, R. J., and van der Hoeven, J. (1998). Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label trial. Journal of Clinical Psychiatry, 59, 56-59.
11. Campbell, M., Anderson, L. T., Meier, M. et al. (1978). A comparison of haloperidol and behavior therapy and their interaction in autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 17, 640-655.
12. Campbell, M., Adams, P., Small, A. M. et al. (1988). Efficacy and safety of fenfluramine in autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 27, 434-439.
13. Campbell, M., Anderson, L. T., Small, A. M. etal. (1993). Naltrexone in autistic children: behavioral symptoms and attentional learning. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 1283-1291.
14. Campbell, M., Armenteros, J. L., Malone, R. P et al. (1997). Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 835-843.
15. Carey, T., Ratliff-Schaub, K., Funk, J. etal. (2002). Double-blind placebo-controlled trial of secretin: effects on aberrant behavior in children with autism. Journal of Autism and Developmental Disorders, 32, 161-167.
16. Carlsson, M. L. (1998). Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate-serotonin interactions for pharmacotherapy. Journal of Neural Transmission, 105, 525-535.
17. Carter, C. S., Williams, J. R., Witt, D. M., and Insel T. R. (1992). Oxytocin and social bonding. Annals of the New York Academy of Science, 652, 204-211.
18. Chez, M. G., Nowinski, C. V, Buchanan, C. P., and Jones, C. (2000). Donepezil use in children with autistic spectrum disorders. American Neurological Association Annual Meeting [abstract].
19. Chez, M. G., Buchanan, C. P., Aimonovitch, M. C. etal. (2002). Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. Journal of Child Neorology, 17, 833-837.
20. Cohen, I. L., Campbell, M., Posner, D. et al. (1980). Behavioral effects of haloperidol in young autistic children. Journal ofthe American Academy ofChild and Adolescent Psychiatry, 19, 665-677.
21. Cohen, S. A., Fitzgerald, B. J., Khan, S. R., andKhan, A. (2004). The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review ofnaturalistic, open-label treatment. Journal of Clinical Psychiatry, 65, 110-113.
22. Coniglio, S. J., Lewis, J. D., Lang, C., and Burns, T. G. (2001). Arandomized, double-blind, placebo- controlled trial of single-dose intravenous secretin as a treatment for children with autism. Journal of Pediatrics, 138, 649-655.
23. Conroy, J., Meally, E., Kearney, G. etal. (2004). Serotonin transporter gene and autism: ahaplotype analysis in an Irish autistic population. Molecular Psychiatry, 9, 587-593.
24. Cook, E. H. (1990). Autism: review of neurochemical investigation. Synapse, 6, 292-308.
25. Corbett, B., Khan, K., Czapansky-Beilman, D., and Brady, N. (2001). A double-blind, placebo- controlled crossover study investigating the effect of porcine secretin in children with autism. Clinical Pediatrics, 40, 327-331.
26. Couturier, J. L. and Nicolson, R. (2002). A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 12, 243-248.
27. Coyle, J. T. (1996). The glutaminergic dysfunction hypothesis for schizophrenia. Harvard Review ofPsychiatryy, 3, 241-253.
28. Davanzo, P. A., Belin, T. R., Widawski, M. H., and King, B. H. (1998). Paroxetine treatment of aggression and self-injury in persons with mental retardation. American Journal of Mental Retardation, 102, 427-437.
29. DeLong, G. R., Ritch, C. R., and Burch, S. (2002). Fluoxetine response in children with autistic spectrum disorders, correlation with familial major affective disorder and intellectual achievement. Developmental Medicine and Child Neurology, 44, 652-659.
30. Drago, F., Pedersen, C. A., Caldwell, J. D., andPrange, A. J. Jr. (1986). Oxytocin potently enhances novelty-induced grooming behavior in the rat. Brain Research, 368, 287-295.
31. Dunn-Geier, J. Ho, H. H., Auersperg, E., and Coyle, D. (2000). Effect of secretin on children with autism: a randomized controlled trial. Developmental Medicine and Child Neurology, 42, 796-802.
32. Einat, H. and Belmaker, R. H. (2001). The effects of inositol treatment in animal models of psychiatric disorders. Journal of Affective Disorders, 62, 113-121.
33. Epperson, C. N., McDougle, C. J., and Anand, A. (1994). Lithium augmentation of fluvoxamine in autistic disorder: a case report. Journal ofChild and Adolescent Psychopharmacology, 4, 201-207.
34. Fankhauser, M. P., Karumanchi, V C., German, M. L., Yates, A., and Karumanchi, S. D. (1992). A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Journal of Clinical Psychiatry, 53, 77-82.
35. Fatemi, S. H., Realmuto, G. M., Khan, L., and Thuras, P. (1998). Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. Journal of Autism and Developmental Disorders, 28, 303-307.
36. Feldman, H. M., Kolman, B. K., and Gonzaga, A. M. (1999). Naltexone and communication skills in young children with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 587-593.
37. Freed, W J. (1984). N, N-Dimethylglycine, betaine, and seizures. Archives of Neurology, 41, 1129-1130.
38. Gillberg, C., Terenius, L., and Lonnerholm, G. (1985). Endorphin activity in childhood psychosis. Archives ofGeneral Psychiatry, 42, 780-783.
39. Gillberg, C. Svennerholm, L., and Hamilton-Hellberg, C. (1983). Childhood psychosis and monoamine metabolites in spinal fluid. Journal of Autism and Developmental Disorders, 13, 383-396.
40. Gobbi, G. and Pulvirenti, L. (2001). Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behavior. Journal of Psychiatry andNeuroscience, 26,340-341.
41. Goff, D. C., Tsai, G., Levitt, J. et al. (1999). A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry, 56, 21-27.
42. Gordon, C. T., State, R. C., Nelson, J. E., Hamburger, S. D., and Rapoport, J. L. (1993). A doubleblind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50, 441-447.
43. Greist, J. H., Jefferson, J. W, Kobak, K. A., Katzelnick, D. J., and Serlin R. C. (1995). Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A metaanalysis. Archives of General Psychiatry, 52, 53-60.
44. Handen, B. L., Johnson, C. R., and Lubetsky, M. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30, 245-255.
45. Harden, A. Y. and Handen, B. L. (2002). A retrospective open trial of adjunctive donepezilin children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 12, 237-41.
46. Herault, J., Petit, E., Martineau, J. et al. (1996). Serotonin and autism: biochemical and molecular biology features. Psychiatry Research, 65, 33-43.
47. Hollander, E., Kaplan, A., Cartwright, C., and Reichman, D. (2000). Venlafaxine in children, adolescents and young adults with autism spectrum disorders: an open retrospective clinical report. Journal of Child Neurology, 15, 132-135.
48. Hollander, E., Dolgoff-Kaspar, R., Cartwright, C., Rawitt, R., and Novotny, S. (2001). An open trial of divalproex sodium in autism spectrum disorders. Journal of Clinical Psychiatry, 62, 530-534.
49. Hollander, E., Novotny, S., Hanratty, M. etal. (2003). Oxytocin infusion reduces repetitivebehaviors in adults with autistic and Asperger’s disorders. Neuropsychopharmacology, 28, 193-198.
50. Horning, M. S., Blakemore, L. J., and Trombley, P. Q. (2000). Endogenous mechanisms of neuroprotection: role of zinc, copper, and carnosine. Brain Research, 852, 56-61.
51. Horvath, K., Stefanatos, G., Sokolski, K. N. et al. (1998). Improved social and language skills after secretin administration in patients with autistic spectrum disorder. Journal of the American Association for Academic Minority Physicians, 9, 9-15.
52. Insel, T. R. and Hulihan, T. J. (1995). A gender-specific mechanism for pair bonding: oxytocin and partner preference formation in monogamous voles. Behavioral Neuroscience, 109, 782-789.
53. Insel T. R. and Winslow J. T. (1991). Central administration of oxytocin modulates the infant rat’s response to social isolation. European Journal of Pharmacology, 203, 149-152.
54. Jaselskis, C. A., Cook, E. H. Jr., Fletcher, K. E., and Levanthal, B. L. (1992). Clonidine treatment ofhyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12, 322-327.
55. Kemner, C., Willemsen-Swinkels, S. H., de Jonge, M., Tuynman-Qua, H., and van Engeland, H. (2002). Open-label study of olanzapine in children with pervasive developmental disorder. Journal ofClinical Psychopharmacology, 22, 455-460.
56. Kerbeshian, J., Burd, L., and Fisher, W (1987). Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomology Journal of Clinical Psychopharmacology, 7, 401-405.
57. Kern, J. K., Miller, V S., Cauller, L. etal. (2001). Effectiveness of N, N-dimethylglycine in autism and pervasive developmental disorder. Journal of Child Neurology, 16, 169-173.
58. Kern, J. K., Miller, V S., Evans, P. A., and Trivendi, M. H. (2002). Efficacy of porcine secretin in children with autism and pervasive developmental disorder. Journal ofAutism andDevelopmental Disorder, 32, 153-160.
59. King, B. H. and Davanzo, P. (1996). Buspirone treatment of aggression self-injury in autistic and nonautistic persons with severe mental retardation. Developmental Brain Dysfuntion, 9, 22-31.
60. King, B. H., Wright, D. M., Handen, B. L. et al. (2001). Double-blind placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 658-665.
61. Krystal, J. H., Belger, A., and D’Souza, D. C. (1999). Therapeutic implications of the hyperglu- taminergic effects of NMDA antagonists. Neuropsychopharmacology, 22, S143-S157.
62. Kumandas, S., Caksen, H., Ciftci, A., Ozturk, M., and Per, H. (2001). Lamotrigine in two cases of Rett syndrome. Brain and Development, 23, 240-242.
63. Lake, C. R., Ziegler, M. G., andMurphy, D. L. (1977). Increased norepinephrine levels anddecreased dopamine-13-hydroxylase activity in primary autism. Archives of General Psychiatry, 34, 553-556.
64. Leboyer, M., Bouvard, M. P., Launay, J. M. et al. (1992). Brief report: a double-blind study of naltrexone in infantile autism. Journal ofAutism and Developmental Disorders, 22, 309-319.
65. Levin, J., Aviram, A., Holan, A. etal. (1997). Inositol treatment of autism. Journal of Neural Transmission, 104, 307-310.
66. Malloy, C. A., Manning-Courtney P., Swayne, S. etal. (2002). Lack ofbenefit of intravenous synthetic human secretin in the treatment of autism. Journal ofAutism and Developmental Disorders, 32, 545-551.
67. Malone, R. P., Cater, J., Sheikh, R. M., Choudhury, M. S., and Delaney, M. A. (2001). Olanazapine versus haloperidol in children with autistic disorder: an open label pilot study Journal of the American Academy ofChild and Adolescent Psychiatry, 40, 887-894.
68. Malone, R. P., Maislin, G., Choudhury, M. S., Gifford, C., and Delaney, M. A. (2002). Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 140-147.
69. Marshall, B. L., Napolitano, D. A., McAdam, D. B. etal. (2003). Venlafaxine and increased aggression in a female with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 383-384.
70. Martin, A., Koenig, K., Scahill, L., and Bregman, J. (1999). Open-label quetiapine in the treatment of children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 9, 99-107.
71. Masi, G., Cosenza, A., Mucci, M., and Brovedani, P. (2001). Open trial of risperidone in 24 young children with pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 1206-1214.
72. Masi, G., Cosenza, A., Mucci, M., and Brovedani, P. (2003). A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. Journal of Clinical Psychiatry, 64, 1039-1047.
73. McDougle, C. J. (2002). Current and emerging therapeutics of autistic disorder and related pervasive developmental disorders. In David, K. L., Charney, D., Coyle, J. T., and Nemeroff, C., eds., Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia: Lippincott, Williams & Wilkins, 565-576.
74. McDougle, C. J., Price, L. H., and Volkmar, F. R. (1994). Recent advances in the pharmacotherapy of autism and related conditions. In F. R. Volkmar, ed., Child and Adolescent Psychiatric Clinics of North America. Vol. 3. Psychoses and Pervasive Developmental Disorders. Philadelphia: W B. Saunders, 71-89.
75. Mc Dougle, C.J.Naylor, S. Cohen, D.J. etal. (1996a). Effects of typtophan depletion in drug-free adults with autism. Archives of General Psychiatry, 53, 993-1000.
76. Mc Dougle, C. J., Naylor, S. T., Cohen, D.J. etal. (1996b). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53, 1001-1008.
77. Mc Dougle, C.J., Holmes, J. P., Carlson, D. C. etal. (1998a). Adouble-blindplacebo-controlledstudy of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry, 55, 633-641.
78. Mc Dougle, C. J., Brodkin, E. S., Naylor, S. T. et al. (1998b). Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. Journal of Clinical Psychopharmacology, 18, 62-66.
79. Mc Dougle, C. J., Kem, D. L., and Posey, D.J. (2002). Case series: use of ziprasidone for maladaptive symptoms in youths with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 921-927.
80. Minderaa, R. B. Anderson, G. M., Volkmar, F. R., Akkerhuis, G. W, and Cohen, D. J. (1994). Noradrenergic and adrenergic functioning in autism. Biological Psychiatry, 36, 237-241.
81. Modahl, C., Green, L., Fein, D. et al. (1998). Plasma oxytocin levels in autistic children. Biologic Psychiatry, 43, 270-277.
82. Namerow, L. B., Thomas, P., Bostic, J. Q., Prince, J., and Montuteaux, M. C. (2003). Useofcitalopram in pervasive developmental disorders. Developmental and Behavioral Pediatrics, 24, 104-108.
83. Nelson E. and Alberts J. R. (1997). Oxytocin-induced paw sucking in infant rats. Annals ofthe New York Academy of Science, 807, 543-545.
84. Niederhofer, H., Staffen, W, and Mair, A. (2002). Lofexidine in hyperactive andimpulsive children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1396-1397.
85. Niederhofer, H., Staffen, W, and Mair, A. (2003). Tianeptine: a novel strategy of psychopharma- cological treatment of children with autistic disorder. Human Psychopharmacology, 18, 389-393.
86. Owley, T., McMahon, W, Cook, E. H. etal. (2001). Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 1293-1299.
87. Percy, A. K., Glaze, D. G., Schultz, R. J. et al. (1994). Rett syndrome: controlled study of an oral opiate antagonist, naltrexone. Annals ofNeurology, 35, 464-470.
88. Perry, R., Campbell, M., Adams, P. et al. (1989). Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. Journal of the American Academy of Child and Adolescent Psychiatry, 28, 87-92.
89. Popik, P. and van Ree, J. M. (1992). Long-term facilitation ofsocial recognition in rats byvasopressin related peptides: a structure-activity study Life Science50, 567-572.
90. Posey, D.J. and Mc Dougle, C. J. (2000). The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harvard Review ofPsychiatry, 8, 45-63.
91. Posey, D. J., Litwiller, M., Koburn, A., andMcDougle, C. J. (1999). Paroxetine in autism. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 111-112.
92. Posey, D. J., Guenin, K. D., Kohn, A. E., Swiezy, N. B., and McDougle, C. J. (2001). A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 11, 267-277.
93. Posey, D. J., Puntney, J. I., Sasher, T. M. et al. (2004a). Guanfacine treatment of hyperactivity and inattention in autism: a retrospective analysis of 80 cases. Journal of Child and Adolescent Psychopharmacology, 14, 233-241.
94. Posey, D.J., Kem, D. L., Swiezy, N. B. etal. (2004b). Apilot study of D-cycloserine in autistic disorder. American Journal ofPsychiatry, 161, 2115-2117.
95. Potenza, M. N., Holmes, J. P., Kanes, S. J., and McDougle, C. J. (1999). Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study Journal of Clinical Psychopharmacology, 19,37-44.
96. Quintana, H., Birmaher, B., Stedge, D. et al. (1995). Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders, 25, 283-295.
97. Ratey, J. J., Bemporad, J., Sorgi, J. et al. (1987a). Brief report: open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults. Journal ofAutism and Developmental Disorders, 17, 439-446.
98. Ratey, J. J., Mikkelsen, E., Sorgi, P. et al. (1987b). Autism: the treatment of aggressive behaviors. Journal of Clinical Psychopharmacology, 7, 35-41.
99. Reap, E. and Lawson, J. (1990). Stimulation of the immune system by dimethylglycine, a nontoxic metabolite. Journal of Laboratory and Clinical Medicine, 115, 481-486.
100. Remington, G., Sloman, L., Konstantareas, M., Parker, K., and Gow, R. (2001). Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal ofClinical Psychopharmacology, 21, 440-444.
101. Research Units on Pediatric Psychopharmacology Autism Network(2002). Risperidone in children with autism and serious behavior problems. New England Journal of Medicine, 347, 314-321.
102. Roberts, W, Weaver, L., Brian, J., and Bryson, S. (2001). Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo controlled trial. Pediatrics, 107, E71.
103. Ross, D. L., Klykylo, W M., and Hitzemann, R. (1987). Reduction of elevated CSF beta-endorphin by fenfluramine in infantile autism. Pediatric Neurology, 3, 83-86.
104. Rugino, T. A. and Samsock, T. C. (2002). Levetiracetam in autistic children: an open-label study Developmental and Behavioral Pediatrics, 23, 225-230.
105. Sandler, A. D., Sutton, K. A., DeWeese, J. et al. (1999). Lack of benefit of single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. NewEngland Journal of Medicine, 341, 1801-1806.
106. Schain, R. J. and Freedman, D. X. (1961). Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. Journal of Pediatrics, 58, 315-320.
107. Snead, R. W, Boon, F., and Presberg, J. (1994). Paroxetine for self-injurious behavior. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 909-910.
108. Sponheim, E., Oftedal, G., and Helverschou, B. (2002). Multiple doses of secretin in the treatment of autism: a controlled study. Acta Paediatrica, 91, 540-545.
109. Stavrakaki, C., Antochi, R., and Emery, P. C. (2004). Olanazpine in the treatment of pervasive developmental disorders: a case series analysis. Journal of Psychiatry and Neuroscience, 29, 57-60.
110. Steingard, R. and Biederman, J. (1987). Lithium-responsive manic-like symptoms in two individuals with autism and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 932-935.
111. Steingard, R. J., Zimnitsky, B., DeMaso, D. R. Bauman, M. L., and Bucci, J. P. (1997). Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. Journal ofChild and Adolescent Psychopharmacology, 7, 9-15.
112. Stern, L. M., Walker, M. K., Sawyer, M. G. etal. (1990). A controlled crossover trial of fenfluramine in autism. Journal of Child Psychology and Psychiatry, 31, 569-585.
113. Stigler, K. A., Posey, D. J., and McDougle, C. J. (2003). Drug therapy algorithms target autism’s problem behaviors. Current Psychiatry, 2, 33-48.
114. Unis, I. S., Munson, J. A., Rogers, S. J. etal. (2002). A randomized, double-blind, placebo controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1315-1321.
115. Uvebrant, P. and Bauziene, R. (1994). Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics, 25, 284-288.
116. Varley, C. K. and Holm, V. A. (1990). A two-year follow-up of autistic children treated with fenfluramine. Journal of the American Academy of Child and Adolescent Psychiatry, 29, 137-140.
117. Wagstaff, A. J., Ormrod, D., and Spencer, C. M. (2001). Tianeptine: a review of its use in depressive disorders. CNS Drugs, 15, 231-259.
118. Weizman, R., Weizman, A., Thano, S. et al. (1984). Humoral-endorphin blood levels in autistic, schizophrenic and healthy subjects. Psychopharmacology, 82, 368-370.
119. Willemsen-Swinkels, S. H. N., Buitelaar, J. K, Nijhof, G. J., and van Engeland, H. (1995). Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retardedadults: double-blindplacebo-controlledstudies. ArchivesofGeneralPsychiatry, 52,766-773.
120. Witt, D. M., Winslow, J. T., and Insel, T. R. (1992). Enhanced social interactions in rats following chronic, centrally infused oxytocin. Pharmacology, Biochemistry, and Behavior, 43, 855-861.
121. Young, J. G., Cohen, D. J., Kavanagh, M. E. etal. (1981). Cerobrospinal fluid, plasma, and urinary MHPG in children. Life Sciences, 28, 2837-2845.
122. Zuddas, A. Ledda, M. G., Fratta, A., Muglia P., and Cianchetti, C. (1996). Clinical effects of clozapine on autistic disorder. American Journal ofPsychiatry, 153, 738.